Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis
As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the b...
Main Authors: | M. Anthony Sofia, David T. Rubin |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-07-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X16643242 |
Similar Items
-
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.
by: Haridarshan Patel, et al.
Published: (2017-01-01) -
Ulcerative colitis - treatment with biologicals
by: Fabio Vieira Teixeira, et al.
Published: (2019-05-01) -
Current approaches to the management of new-onset ulcerative colitis
by: Marchioni Beery R, et al.
Published: (2014-05-01) -
Golimumab Therapy in Ulcerative Colitis
by: Won Moon
Published: (2016-02-01) -
Nicotine therapy for ulcerative colitis
by: Thomas, Gareth Andrew Osbert
Published: (1995)